CO6241155A2 - [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo - Google Patents

[4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo

Info

Publication number
CO6241155A2
CO6241155A2 CO09132279A CO09132279A CO6241155A2 CO 6241155 A2 CO6241155 A2 CO 6241155A2 CO 09132279 A CO09132279 A CO 09132279A CO 09132279 A CO09132279 A CO 09132279A CO 6241155 A2 CO6241155 A2 CO 6241155A2
Authority
CO
Colombia
Prior art keywords
salt
ion
ilo
sulfonylide
thiophen
Prior art date
Application number
CO09132279A
Other languages
English (en)
Inventor
Emma Sharp
Louisa Jane Quegan
Wolin Huang
Matthew Nieder
Juan Wang
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of CO6241155A2 publication Critical patent/CO6241155A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una sal que contiene un compuesto de la Fórmula I.Y un ión seleccionado del grupo consistente de calcio, L-lisina, amonio, magnesio, L-arginina, trometamina, N-etilglucamina y N-metilglucamina. 2.- La sal de la reivindicación 1, en donde el ión es potasio. 3.- La sal de la reivindicación 1, en donde el ión es sodio. 4.- La sal de la reivindicación 1, en donde el ión es calcio. 5.- La sal de la reivindicación 1, en donde el ión es L-lisina.6.- La sal de la reivindicación 1, en donde el ión es amonio. 7.- La sal de la reivindicación 1, en donde el ión es magnesio. 8.- La sal de la reivindicación 1, en donde el ión es L-arginina. 9.- La sal de la reivindicación 1, en donde el ión es trometamina. 10.- La sal de la reivindicación 1, en donde el ión es N-etilglucamina. 11.- La sal de la reivindicación 1, en donde el ión es N-metilglucamina. 12.- Una sal que contiene la fórmulaEn una forma sólida cristalina C caracterizada por lo menos por: (i) un patrón de difracción de polvos de rayos-X substancialmente de acuerdo con la Figura 20b; y (ii) Un escaneo DSC substancialmente de acuerdo con la Figura 25. 13.- La sal de la Reivindicación 12 en una forma sólida cristalina C caracterizada por un patrón de difracción de polvos de rayos-X sustancialmente de acuerdo con la Figura 24.
CO09132279A 2007-05-02 2009-11-20 [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo CO6241155A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02

Publications (1)

Publication Number Publication Date
CO6241155A2 true CO6241155A2 (es) 2011-01-20

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09132279A CO6241155A2 (es) 2007-05-02 2009-11-20 [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo

Country Status (18)

Country Link
US (1) US20090042916A1 (es)
EP (1) EP2076510A2 (es)
JP (1) JP2010526105A (es)
KR (1) KR20100020455A (es)
CN (1) CN101720324A (es)
AU (1) AU2008247457A1 (es)
BR (1) BRPI0810800A2 (es)
CA (1) CA2686221A1 (es)
CO (1) CO6241155A2 (es)
EA (1) EA200901474A1 (es)
EC (1) ECSP099779A (es)
GT (1) GT200900282A (es)
IL (1) IL201829A0 (es)
MA (1) MA31397B1 (es)
MX (1) MX2009011836A (es)
TN (1) TN2009000452A1 (es)
WO (1) WO2008137809A2 (es)
ZA (1) ZA200907493B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1951254T3 (da) * 2005-11-03 2012-05-07 Portola Pharm Inc (4-(6-halo-7-substitueret-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl)¨-5-chlorthiophen-2-yl-sulfonylureaer og former og fremgangsmåder der er relateret dertil
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
EP2523657A1 (en) 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
WO2019126557A1 (en) 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2002217999A1 (en) * 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
ATE448222T1 (de) * 2003-10-03 2009-11-15 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
DK1951254T3 (da) * 2005-11-03 2012-05-07 Portola Pharm Inc (4-(6-halo-7-substitueret-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl)¨-5-chlorthiophen-2-yl-sulfonylureaer og former og fremgangsmåder der er relateret dertil
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CN101795682A (zh) * 2007-05-02 2010-08-04 波托拉医药品公司 直接起效和可逆的p2y12抑制剂的静脉内和口服给药

Also Published As

Publication number Publication date
CN101720324A (zh) 2010-06-02
BRPI0810800A2 (pt) 2014-10-29
EP2076510A2 (en) 2009-07-08
GT200900282A (es) 2010-05-21
ECSP099779A (es) 2010-01-29
AU2008247457A1 (en) 2008-11-13
MX2009011836A (es) 2010-05-20
JP2010526105A (ja) 2010-07-29
CA2686221A1 (en) 2008-11-13
KR20100020455A (ko) 2010-02-22
MA31397B1 (fr) 2010-05-03
EA200901474A1 (ru) 2010-04-30
ZA200907493B (en) 2010-07-28
IL201829A0 (en) 2010-06-16
WO2008137809A2 (en) 2008-11-13
TN2009000452A1 (en) 2011-03-31
WO2008137809A3 (en) 2009-01-22
US20090042916A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ES2660773T3 (es) Procedimiento para la preparación de una sal cristalina trialcalino-metálica de L-MGDA
AR121612A2 (es) Inhibidores de glucosilceramida sintasa
ES2563323T3 (es) Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético
RU2013109393A (ru) Безилатная соль ингибитора втк
CL2017001978A1 (es) Producción de compuestos de litio de alta pureza directamente a partir de salmueras que contienen litio
AR073073A1 (es) Compuestos de pirrolo [ 2,3-d] pirimidina.
AR091138A1 (es) Proceso para la preparacion de n-[5-(3,5-difluorobencil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetrahidropiran-4-ilamino)-benzamida
BR112013020609A2 (pt) 2-hidróxi-4-(metiltio) butironitrila estável em armazenamento
CO5650228A2 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
ES2532451T3 (es) Composición herbicida
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
AR102915A1 (es) Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable
UY35009A (es) Composiciones y métodos para mejorar la compatibilidad de sales herbicidas hidrosolubles
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
AR082601A1 (es) Formas cristalinas de compuestos de pirimido[6,1-a]isoquinolin-4-ona
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR090209A1 (es) Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden
CO2021009309A2 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
AR074592A1 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina, procesos e intermediario para su sintesis y su uso en el tratamiento de una enfermedad mediada por un antagonista de los receptores mu opioides.
DK1940772T3 (da) Ny fremgangsmåde til fremstilling af kvaternære syre- og ammoniumsalte
EA201792582A1 (ru) Композиция для придания формы волосам

Legal Events

Date Code Title Description
FC Application refused